

Delcath Systems, Inc. (DCTH)

Market Cap: \$382.8m

JUNE 1, 2026 | CHICAGO & MILWAUKEE



Management

Gerard Michel
Chief Executive Officer

Sandra Pennell
Chief Financial Officer

About Delcath Systems, Inc.

Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (Hepzato (Melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. DCTH is headquartered in Queensbury, NY.

Roadshow Host

Sudan Loganathan, PhD
Managing Director
Biotechnology Research
(212) 891-1762
sudan.loganathan@stephens.com

Space will be limited. Meeting times and itinerary subject to change. To join the event or to obtain more information, please contact your Stephens sales representative.